Inflammatory mediators and angiogenic factors in choroidal neovascularization: Pathogenetic interactions and therapeutic implications

Mediators of Inflammation

Volumn 2010, Issue , 2010, Pages

  Parmeggiani, Francesco ^a   Campa, Claudio ^a,b   Costagliola, Ciro ^c   Incorvaia, Carlo ^a   Sheridan, Carl ^b   Semeraro, Francesco ^d   De Nadai, Katia ^a,e   Sebastiani, Adolfo ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MOLISE   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

^e Camposampiero Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANECORTAVE; ANGIOGENIC FACTOR; ANGIOSTATIN; BEVACIZUMAB; BEVASIRANIB; CHEMOKINE RECEPTOR CCR3; CYTOKINE; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; INFLIXIMAB; NITRIC OXIDE; PAZOPANIB; PEGAPTANIB; PIGMENT EPITHELIUM DERIVED FACTOR; RANIBIZUMAB; RAPAMYCIN; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR; VASCULOTROPIN; VATALANIB;

ANGIOGENESIS; ENDOTHELIUM CELL; HUMAN; INFLAMMATION; INFLAMMATORY CELL; PATHOGENESIS; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; REVIEW; SIGNAL TRANSDUCTION; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; ANIMALS; CHOROIDAL NEOVASCULARIZATION; HUMANS; INFLAMMATION MEDIATORS; MACULAR DEGENERATION;

EID: 77957899993     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2010/546826     Document Type: Review

References (161)

1. Green W. R., Wilson D. J., Choroidal neovascularization Ophthalmology 1986 93 9 1169 1176
2. Klein R., Peto T., Bird A., Vannewkirk M. R., The epidemiology of age-related macular degeneration American Journal of Ophthalmology 2004 137 3 486 495
3. Bressler N. M., Photodynamic therapy of subfoveal choroidal neovascularization in age- related macular degeneration with verteporfin: one-year results of 2 randomized clinical trialsTAP report 1 Archives of Ophthalmology 1999 117 10 1329 1345
4. Arnold J., Barbezetto I., Birngruber R., Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularizationverteporfin in photodynamic therapy report 2 American Journal of Ophthalmology 2001 131 5 541 560
5. Bressler N. M., Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update Retina 2005 25 2 119 134
6. Chakravarthy U., Soubrane G., Bandello F., Evolving European guidance on the medical management of neovascular age related macular degeneration British Journal of Ophthalmology 2006 90 9 1188 1196
7. Gass J. D. M., Stereoscopic Atlas of Macular Diseases: Diagrams and Treatment 1997 1 St. Louis, Mo, USA Mosby
8. Grossniklaus H. E., Green W. R., Choroidal neovascularization American Journal of Ophthalmology 2004 137 3 496 503
9. Killingsworth M. C., Angiogenesis in early choroidal neovascularization secondary to age-related macular degeneration Graefe's Archive for Clinical and Experimental Ophthalmology 1995 233 6 313 323
10. Grossniklaus H. E., Green W. R., Histopathologic and ultrastructural findings of surgically excised choroidal neovascularization Archives of Ophthalmology 1998 116 6 745 749
11. Grossniklaus H. E., Ling J. X., Wallace T. M., Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization Molecular Vision 2002 21 8 119 126
12. Tsutsumi-Miyahara C., Sonoda K. H., Egashira K., Ishibashi M., Qiao H., Oshima T., Murata T., Miyazaki M., Charo I. F., Hamano S., Ishibashi T., The relative contributions of each subset of ocular infiltrated cells in experimental choroidal neovascularisation British Journal of Ophthalmology 2004 88 9 1217 1222
13. Espinosa-Heidmann D. G., Reinoso M. A., Pina Y., Csaky K. G., Caicedo A., Cousins S. W., Quantitative enumeration of vascular smooth muscle cells and endothelial cells derived from bone marrow precursors in experimental choroidal neovascularization Experimental Eye Research 2005 80 3 369 378
14. Sheridan C. M., Rice D., Hiscott P. S., Wong D., Kent D. L., The presence of AC133-positive cells suggests a possible role of endothelial progenitor cells in the formation of choroidal neovascularization Investigative Ophthalmology Visual Science 2006 47 4 1642 1645
15. Spaide R. F., Rationale for combination therapies for choroidal neovascularization American Journal of Ophthalmology 2006 141 1 149 156
16. Lopez P. F., Sippy B. D., Lambert H. M., Thach A. B., Hinton D. R., Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes Investigative Ophthalmology Visual Science 1996 37 5 855 868
17. Kvanta A., Algvere P. V., Berglin L., Seregard S., Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor Investigative Ophthalmology Visual Science 1996 37 9 1929 1934
18. Ishibashi T., Hata Y., Yoshikawa H., Nakagawa K., Sueishi K., Inomata H., Expression of vascular endothelial growth factor in experimental choroidal neovascularization Graefe's Archive for Clinical and Experimental Ophthalmology 1997 235 3 159 167
19. Wada M., Ogata N., Otsuji T., Uyama M., Expression of vascular endothelial growth factor and its receptor (KDR/flk-1) mRNA in experimental choroidal neovascularization Current Eye Research 1999 18 3 203 213 (Pubitemid 29213835)
20. Otani A., Takagi H., Oh H., Koyama S., Ogura Y., Matumura M., Honda Y., Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes Microvascular Research 2002 64 1 162 169
21. Blaauwgeers H. G. T., Holtkamp G. M., Rutten H., Witmer A. N., Koolwijk P., Partanen T. A., Alitalo K., Kroon M. E., Kijlstra A., Van Hinsbergh V. W. M., Schlingemann R. O., Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris: evidence for a trophic paracrine relation American Journal of Pathology 1999 155 2 421 428
22. Ferrara N., Gerber H. P., Le Couter J., The biology of VEGF and its receptors Nature Medicine 2003 9 6 669 676
23. Alitalo K., Tammela T., Petrova T. V., Lymphangiogenesis in development and human disease Nature 2005 438 7070 946 953
24. Ferrara N., Vascular endothelial growth factor: basic science and clinical progress Endocrine Reviews 2004 25 4 581 611 (Pubitemid 39099316)
25. Houck K. A., Leung D. W., Rowland A. M., Winer J., Ferrara N., Dual regulation of vascular endothelial growth factor The Journal of Biological Chemistry 1992 267 36 26031 26037
26. Keyt B. A., Berleau L. T., Nguyen H. V., Chen H., Heinsohn H., Vandlen R., Ferrara N., The carboxyl-terminal domain (111165) of vascular endothelial growth factor is critical for its mitogenic potency The Journal of Biological Chemistry 1996 271 13 7788 7795
27. Lee S., Jilani S. M., Nikolova G. V., Carpizo D., Luisa Iruela-Arispe M., Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors Journal of Cell Biology 2005 169 4 681 691
28. de Vries C., Escobedo J. A., Ueno H., Houck K., Ferrara N., Williams L. T., The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor Science 1992 255 5047 989 991
29. Grossniklaus H. E., Martinez J. A., Brown V. B., Lambert H. M., Sternberg P. Jr., Capone A. Jr., Aaberg T. M., Lopez P. F., Immunohistochemical and histochemical properties of surgically excised subretinal neovascular membranes in age-related macular degeneration American Journal of Ophthalmology 1992 114 4 464 472
30. Frank R. N., Amin R. H., Eliott D., Puklin J. E., Abrams G. W., Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes American Journal of Ophthalmology 1996 122 3 393 403
31. Hera R., Keramidas M., Peoc'h M., Mouillon M., Romanet J. P., Feige J. J., Expression of VEGF and angiopoietins in subfoveal membranes from patients with age-related macular degeneration American Journal of Ophthalmology 2005 139 4 589 596
32. Aiello L. P., Avery R. L., Arrigg P. G., Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders The New England Journal of Medicine 1994 331 22 1480 1487
33. Wells J. A., Murthy R., Chibber R., Nunn A., Molinatti P. A., Kohner E. M., Gregor Z. J., Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation British Journal of Ophthalmology 1996 80 4 363 366
34. Spilsbury K., Garrett K. L., Shen W. Y., Constable I. J., Rakoczy P. E., Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization American Journal of Pathology 2000 157 1 135 144
35. Csaky K. G., Baffi J. Z., Byrnes G. A., Wolfe J. D., Hilmer S. C., Flippin J., Cousins S. W., Recruitment of marrow-derived endothelial cells to experimental choroidal neovascularization by local expression of vascular endothelial growth factor Experimental Eye Research 2004 78 6 1107 1116
36. Krzystolik M. G., Afshari M. A., Adamis A. P., Gaudreault J., Gragoudas E. S., Michaud N. A., Li W., Connolly E., O'Neill C. A., Miller J. W., Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment Archives of Ophthalmology 2002 120 3 338 346
37. Saishin Y., Saishin Y., Takahashi K., Silva R. L. E., Hylton D., Rudge J. S., Wiegand S. J., Campochiaro P. A., VEGF-TRAPR1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier Journal of Cellular Physiology 2003 195 2 241 248
38. Tolentino M. J., Miller J. W., Gragoudas E. S., Chatzistefanou K., Ferrara N., Adamis A. P., Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate Archives of Ophthalmology 1996 114 8 964 970 (Pubitemid 26271462)
39. Sheridan C. M., Pate S., Hiscott P., Wong D., Pattwell D. M., Kent D., Expression of hypoxia-inducible factor-1 and -2 in human choroidal neovascular membranes Graefe's Archive for Clinical and Experimental Ophthalmology 2009 247 10 1361 1367
40. Asahara T., Takahashi T., Masuda H., Kalka C., Chen D., Iwaguro H., Inai Y., Silver M., Isner J. M., VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells The EMBO Journal 1999 18 14 3964 3972 (Pubitemid 29335849)
41. Guerin E., Sheridan C. M., Assheton D., Kent D., Wong D., Grant M., Hiscott P., SDF1-alpha is associated with VEGFR-2 in human choroidal neovascularisation Microvascular Research 2008 75 3 302 307
42. Lamoreaux W. J., Fitzgerald M. E. C., Reiner A., Hasty K. A., Charles S. T., Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro Microvascular Research 1998 55 1 29 42
43. Clauss M., Gerlach M., Gerlach H., Brett J., Wang F., Familletti P. C., Pan Y. C. E., Olander J. V., Connolly D. T., Stern D., Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration Journal of Experimental Medicine 1990 172 6 1535 1545
44. Barleon B., Sozzani S., Zhou D., Weich H. A., Mantovani A., Marm D., Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1 Blood 1996 87 8 3336 3343
45. Espinosa-Heidmann D. G., Suner I. J., Hernandez E. P., Monroy D., Csaky K. G., Cousins S. W., Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization Investigative Ophthalmology Visual Science 2003 44 8 3586 3592
46. Noda K., She H., Nakazawa T., Hafezi-Moghadam A., Vascular adhesion protein-1 blockade suppresses choroidal neovascularization The FASEB Journal 2008 22 8 2928 2935
47. Bian Z. M., Elner S. G., Strieter R. M., Kunkel S. L., Lukacs N. W., Elner V. M., IL-4 potentiates IL-1 -and TNF- -stimulated IL-8 and MCP-1 protein production in human retinal pigment epithelial cells Current Eye Research 1999 18 5 349 357
48. Mousa S. A., Lorelli W., Campochiaro P. A., Role of hypoxia and extracellular matrix-integrin binding in the modulation of angiogenic growth factors secretion by retinal pigmented epithelial cells Journal of Cellular Biochemistry 1999 74 1 135 143
49. Izumi-Nagai K., Nagai N., Ozawa Y., Mihara M., Ohsugi Y., Kurihara T., Koto T., Satofuka S., Inoue M., Tsubota K., Okano H., Oike Y., Ishida S., Interleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularization American Journal of Pathology 2007 170 6 2149 2158
50. Roh M. I., Kim H. S., Song J. H., Lim J. B., Koh H. J., Kwon O. W., Concentration of cytokines in the aqueous humor of patients with naive, recurrent and regressed cnv associated with amd after bevacizumab treatment Retina 2009 29 4 523 529
51. Apte R. S., Richter J., Herndon J., Ferguson T. A., Macrophages inhibit neovascularization in a murine model of age-related macular degeneration PLoS Medicine 2006 3 8, article e310
52. Barouch F. C., Miller J. W., Potential future targets for treating ocular neovascularization Ophthalmology Clinics of North America 2006 19 3 401 409
53. Lambooij A. C., van Wely K. H. M., Lindenbergh-Kortleve D. J., Kuijpers R. W. A. M., Kliffen M., Mooy C. M., Insulin-like growth factor-I and its receptor in neovascular age-related macular degeneration Investigative Ophthalmology Visual Science 2003 44 5 2192 2198
54. Economou M. A., Wu J., Vasilcanu D., Rosengren L., All-Ericsson C., Van Der Ploeg I., Menu E., Girnita L., Axelson M., Larsson O., Seregard S., Kvanta A., Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor Investigative Ophthalmology Visual Science 2008 49 6 2620 2626
55. Moncada S., Palmer R. M. J., Higgs E. A., Nitric oxide: physiology, pathophysiology, and pharmacology Pharmacological Reviews 1991 43 2 109 142
56. Ando A., Yang A., Nambu H., Campochiaro P. A., Blockade of nitric-oxide synthase reduces choroidal neovascularization Molecular Pharmacology 2002 62 3 539 544
57. O'Reilly M. S., Holmgren L., Shing Y., Chen C., Rosenthal R. A., Moses M., Lane W. S., Cao Y., Helene Sage E., Folkman J., Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma Cell 1994 79 2 315 328
58. Lai C. C., Wu W. C., Chen S. L., Xiao X., Tsai T. C., Huan S. J., Chen T. L., Tsai R. J. F., Tsao Y. P., Suppression of choroidal neovascularization by adeno-associated virus vector expressing angiostatin Investigative Ophthalmology Visual Science 2001 42 10 2401 2407
59. O'Reilly M. S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W. S., Flynn E., Birkhead J. R., Olsen B. R., Folkman J., Endostatin: an endogenous inhibitor of angiogenesis and tumor growth Cell 1997 88 2 277 285
60. Mori K., Ando A., Gehlbach P., Nesbitt D., Takahashi K., Goldsteen D., Penn M., Chen C. T., Mori K., Melia M., Phipps S., Moffat D., Brazzell K., Liau G., Dixon K. H., Campochiaro P. A., Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin American Journal of Pathology 2001 159 1 313 320
61. Dawson D. W., Volpert O. V., Gillis P., Crawford S. E., Xu H. J., Benedict W., Bouck N. P., Pigment epithelium-derived factor: a potent inhibitor of angiogenesis Science 1999 285 5425 245 248
62. Saishin Y., Silva R. L., Saishin Y., Kachi S., Aslam S., Yuan Y. G., Lai H., Carrion M., Harris B., Hamilton M., Wei L., Campochiaro P. A., Periocular gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization in a human-sized eye Human Gene Therapy 2005 16 4 473 478
63. Gehlbach P., Demetriades A. M., Yamamoto S., Deering T., Duh E. J., Yang H. S., Cingolani C., Lai H., Wei L., Campochiaro P. A., Periocular injection of an adenoviral vector encoding pigment epithelium-derived factor inhibits choroidal neovascularization Gene Therapy 2003 10 8 637 646
64. Takeda A., Baffi J. Z., Kleinman M. E., Cho W. G., Nozaki M., Yamada K., Kaneko H., Albuquerque R. J. C., Dridi S., Saito K., Raisler B. J., Budd S. J., Geisen P., Munitz A., Ambati B. K., Green M. G., Ishibashi T., Wright J. D., Humbles A. A., Gerard C. J., Ogura Y., Pan Y., Smith J. R., Grisanti S., Hartnett M. E., Rothenberg M. E., Ambati J., CCR3 is a target for age-related macular degeneration diagnosis and therapy Nature 2009 460 7252 225 230
65. De La Paz M. A., Itoh Y., Toth C. A., Nagase H., Matrix metalloproteinases and their inhibitors in human vitreous Investigative Ophthalmology Visual Science 1998 39 7 1256 1260
66. Steen B., Sejersen S., Berglin L., Seregard S., Kvanta A., Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes Investigative Ophthalmology Visual Science 1998 39 11 2194 2200
67. Lambert V., Munaut C., Jost M., Nol A., Werb Z., Foidart J. M., Rakic J. M., Matrix metalloproteinase-9 contributes to choroidal neovascularization American Journal of Pathology 2002 161 4 1247 1253
68. Lambert V., Wielockx B., Munaut C., MMP-2 and MMP-9 synergize in promoting choroidal neovascularization The FASEB Journal 2003 17 15 2290 2292
69. Takahashi T., Nakamura T., Hayashi A., Kamei M., Nakabayashi M., Okada A. A., Tomita N., Kaneda Y., Tano Y., Inhibition of experimental choroidal neovascularization by overexpression of tissue inhibitor of metalloproteinases-3 in retinal pigment epithelium cells American Journal of Ophthalmology 2000 130 6 774 781
70. Otani A., Takagi H., Oh H., Koyama S., Matsumura M., Honda Y., Expressions of angiopoietins and Tie2 in human choroidal neovascular membranes Investigative Ophthalmology Visual Science 1999 40 9 1912 1920
71. Lu M., Adamis A. P., Molecular biology of choroidal neovascularization Ophthalmology Clinics of North America 2006 19 3 323 334
72. Amin R., Puklin J. E., Frank R. N., Growth factor localization in choroidal neovascular membranes of age- related macular degeneration Investigative Ophthalmology Visual Science 1994 35 8 3178 3188
73. Ogata N., Yamamoto C., Miyashiro M., Yamada H., Matsushima M., Uyama M., Expression of transforming growth factor- mRNA in experimental choroidal neovascularization Current Eye Research 1997 16 1 9 18 (Pubitemid 27085147)
74. Hu W., Criswell M. H., Fong S. L., Temm C. J., Rajashekhar G., Cornell T. L., Clauss M. A., Differences in the temporal expression of regulatory growth factors during choroidal neovascular development Experimental Eye Research 2009 88 1 79 91
75. Bora P. S., Sohn J. H., Cruz J. M. C., Jha P., Nishihori H., Wang Y., Kaliappan S., Kaplan H. J., Bora N. S., Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization The Journal of Immunology 2005 174 1 491 497
76. Hageman G. S., Anderson D. H., Johnson L. V., Hancox L. S., Taiber A. J., Hardisty L. I., Hageman J. L., Stockman H. A., Borchardt J. D., Gehrs K. M., Smith R. J. H., Silvestri G., Russell S. R., Klaver C. C. W., Barbazetto I., Chang S., Yannuzzi L. A., Barile G. R., Merriam J. C., Smith R. T., Olsh A. K., Bergeron J., Zernant J., Merriam J. E., Gold B., Dean M., Allikmets R., A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration Proceedings of the National Academy of Sciences of the United States of America 2005 102 20 7227 7232
77. Edwards A. O., Ritter R. III, Abel K. J., Manning A., Panhuysen C., Farrer L. A., Complement factor H polymorphism and age-related macular degeneration Science 2005 308 5720 421 424
78. Haines J. L., Hauser M. A., Schmidt S., Scott W. K., Olson L. M., Gallins P., Spencer K. L., Shu Y. K., Noureddine M., Gilbert J. R., Schnetz-Boutaud N., Agarwal A., Postel E. A., Pericak-Vance M. A., Complement factor H variant increases the risk of age-related macular degeneration Science 2005 308 5720 419 421
79. Klein R. J., Zeiss C., Chew E. Y., Tsai J. Y., Sackler R. S., Haynes C., Henning A. K., SanGiovanni J. P., Mane S. M., Mayne S. T., Bracken M. B., Ferris F. L., Ott J., Barnstable C., Hoh J., Complement factor H polymorphism in age-related macular degeneration Science 2005 308 5720 385 389
80. Wegscheider B. J., Weger M., Renner W., Steinbrugger I., Mrz W., Mossbck G., Temmel W., El-Shabrawi Y., Schmut O., Jahrbacher R., Haas A., Association of complement factor H Y402H gene polymorphism with different subtypes of exudative age-related macular degeneration Ophthalmology 2007 114 4 738 742 (Pubitemid 46483679)
81. Seddon J. M., Francis P. J., George S., Schultz D. W., Rosner B., Klein M. L., Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration Journal of the American Medical Association 2007 297 16 1793 1800
82. Brantley M. A. Jr., Edelstein S. L., King J. M., Apte R. S., Kymes S. M., Shiels A., Clinical phenotypes associated with the complement factor H Y402H variant in age-related macular degeneration American Journal of Ophthalmology 2007 144 3 404 408
83. Seitsonen S. P., Onkamo P., Peng G., Multifactor effects and evidence of potential interaction between complement factor HY402H and LOC387715 A69S in age-related macular degeneration PLoS ONE 2008 3 12, article e3833
84. Shuler R. K. Jr., Schmidt S., Gallins P., Hauser M. A., Scott W. K., Caldwell J., Agarwal A., Haines J. L., Pericak-Vance M. A., Postel E. A., Phenotype analysis of patients with the risk variant LOC387715 (A69S) in age-related macular degeneration American Journal of Ophthalmology 2008 145 2 303 307
85. Droz I., Mantel I., Ambresin A., Faouzi M., Schorderet D. F., Munier F. L., Genotype-phenotype correlation of age-related macular degeneration: influence of complement factor H polymorphism British Journal of Ophthalmology 2008 92 4 513 517
86. Kim N. R., Kang J. H., Kwon O. W., Lee S. J., Oh J. H., Chin H. S., Association between complement factor H gene polymorphisms and neovascular age-related macular degeneration in koreans Investigative Ophthalmology Visual Science 2008 49 5 2071 2076
87. Kaur I., Katta S., Hussain A., Hussain N., Mathai A., Narayanan R., Hussain A., Reddy R. K., Majji A. B., Das T., Chakrabarti S., Variants in the 10q26 gene cluster (LOC387715 and HTRA1) exhibit enhanced risk of age-related macular degeneration along with CFH in Indian patients Investigative Ophthalmology Visual Science 2008 49 5 1771 1776
88. Deangelis M. M., Ji F., Adams S., Morrison M. A., Harring A. J., Sweeney M. O., Capone A. Jr., Miller J. W., Dryja T. P., Ott J., Kim I. K., Alleles in the HtrA serine peptidase 1 gene alter the risk of neovascular age-related macular degeneration Ophthalmology 2008 115 7 1209 1215
89. Leveziel N., Zerbib J., Richard F., Querques G., Morineau G., Fremeaux-Bacchi V., Coscas G., Soubrane G., Benlian P., Souied E. H., Genotype-phenotype correlations for exudative age-related macular degeneration associated with homozygous HTRA1 and CFH genotypes Investigative Ophthalmology Visual Science 2008 49 7 3090 3094
90. Gotoh N., Yamada R., Nakanishi H., Saito M., Iida T., Matsuda F., Yoshimura N., Correlation between CFH Y402H and HTRA1 rs11200638 genotype to typical exudative age-related macular degeneration and polypoidal choroidal vasculopathy phenotype in the Japanese population Clinical and Experimental Ophthalmology 2008 36 5 437 442
91. Xu Y., Guan N., Xu J., Yang X., Ma K., Zhou H., Zhang F., Snellingen T., Jiao Y., Liu X., Wang N., Liu N., Association of CFH, LOC387715, and HTRA1 polymorphisms with exudative age-related macular degeneration in a northern Chinese population Molecular Vision 2008 14 1373 1381
92. Ricci F., Zampatti S., D'Abbruzzi F., Missiroli F., Martone C., Lepre T., Pietrangeli I., Sinibaldi C., Peconi C., Novelli G., Emiliano G., Typing of ARMS2 and CFH in age-related macular degeneration: case-control study and assessment of frequency in the Italian population Archives of Ophthalmology 2009 127 10 1368 1372
93. Francis P. J., Zhang H., DeWan A., Hoh J., Klein M. L., Joint effects of polymorphisms in the HTRA1, LOC387715/ARMS2, and CFH genes on AMD in a Caucasian population Molecular Vision 2008 14 1395 1400
94. Kim I. K., Ji F., Morrison M. A., Adams S., Zhang Q., Lane A. M., Capone A., Dryja T. P., Ott J., Miller J. W., DeAngelis M. M., Comprehensive analysis of CRP, CFH Y402H and environmental risk factors on risk of neovascular age-related macular degeneration Molecular Vision 2008 14 1487 1495
95. Klein R., Knudtson M. D., Klein B. E., Wong T. Y., Cotch M. F., Liu K., Cheng C. Y., Burke G. L., Saad M. F., Jacobs D. R. Jr., Sharrett A. R., Inflammation, complement factor H, and age-related macular degeneration: the multi-ethnic study of atherosclerosis Ophthalmology 2008 115 10 1742 1749
96. Marioli D. I., Pharmakakis N., Deli A., Havvas I., Zarkadis I. K., Complement factor H and LOC 387715 gene polymorphisms in a Greek population with age-related macular degeneration Graefe's Archive for Clinical and Experimental Ophthalmology 2009 247 11 1547 1553
97. Jiang H., Qu Y., Dang G., Zhang X., Yin N., Zhang Y., Bi H., Pan X., Xu X., Zhou F., Dai H., Analyses of single nucleotide polymorphisms and haplotype linkage of LOC387715 and the HTRA1 gene in exudative age-related macular degeneration in a Chinese cohort Retina 2009 29 7 974 979
98. Reynolds R., Hartnett M. E., Atkinson J. P., Giclas P. C., Rosner B., Seddon J. M., Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes Investigative Ophthalmology Visual Science 2009 50 12 5818 5827
99. Lederman M., Weiss A., Chowers I., Association of neovascular age-related macular degeneration with specific gene expression patterns in peripheral white blood cells Investigative Ophthalmology Visual Science 2010 51 1 53 58
100. Kaur I., Katta S., Reddy R. K., Narayanan R., Mathai A., Majji A. B., Chakrabarti S., The involvement of complement factor B and complement component C2 in an Indian cohort with age-related macular degeneration Investigative Ophthalmology Visual Science 2010 51 1 59 63
101. Francis P. J., Hamon S. C., Ott J., Weleber R. G., Klein M. L., Polymorphisms in C2, CFB and C3 are associated with progression to advanced age related macular degeneration associated with visual loss Journal of Medical Genetics 2009 46 5 300 307
102. de Crdoba S. R., de Jorge E. G., Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H Clinical and Experimental Immunology 2008 151 1 1 13
103. Hageman G. S., Hancox L. S., Taiber A. J., Gehrs K. M., Anderson D. H., Johnson L. V., Radeke M. J., Kavanagh D., Richards A., Atkinson J., Meri S., Bergeron J., Zernant J., Merriam J., Gold B., Allikmets R., Dean M., Hageman J., Hoballah J., Stockman H., Immonen I., Laine M., Jarva H., Jrvel I., Seitsonen S., Barile G., Chang S., Merriam J. C., Smith R. T., Yannuzzi L. A., Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: characterization, ethnic distribution and evolutionary implications Annals of Medicine 2006 38 8 592 604
104. Machaliska A., Dziedziejko V., Mozolewska-Piotrowska K., Karczewicz D., Wiszniewska B., MacHaliski B., Elevated plasma levels of C3a complement compound in the exudative form of age-related macular degeneration Ophthalmic Research 2009 42 1 54 59
105. Jain R. K., Molecular regulation of vessel maturation Nature Medicine 2003 9 6 685 693
106. Gaengel K., Genov G., Armulik A., Betsholtz C., Endothelial-mural cell signaling in vascular development and angiogenesis Arteriosclerosis, Thrombosis, and Vascular Biology 2009 29 5 630 638
107. Thomas M., Augustin H. G., The role of the angiopoietins in vascular morphogenesis Angiogenesis 2009 12 2 125 137
108. Jo N., Mailhos C., Ju M., Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization American Journal of Pathology 2006 168 6 2036 2053
109. Kent D., Sheridan C., Choroidal neovascularization: a wound healing perspective Molecular Vision 2003 9 747 755
110. Ferrara N., Mass R. D., Campa C., Kim R., Targeting VEGF-A to treat cancer and age-related macular degeneration Annual Review of Medicine 2007 58 491 504
111. Gragoudas E. S., Adamis A. P., Cunningham E. T. Jr., Feinsod M., Guyer D. R., Pegaptanib for neovascular age-related macular degeneration The New England Journal of Medicine 2004 351 27 2805 2816
112. Chakravarthy U., Adamis A. P., Cunningham E. T. Jr., Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration Ophthalmology 2006 113 9 1508 1521
113. Rosenfeld P. J., Brown D. M., Heier J. S., Ranibizumab for neovascular age-related macular degeneration The New England Journal of Medicine 2006 355 14 1419 1431
114. Brown D. M., Kaiser P. K., Michels M., Ranibizumab versus verteporfin for neovascular age-related macular degeneration The New England Journal of Medicine 2006 355 14 1432 1444
115. Brown D. M., Michels M., Kaiser P. K., Heier J. S., Sy J. P., Ianchulev T., Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study Ophthalmology 2009 116 1 57 65
116. Avery R. L., Pieramici D. J., Rabena M. D., Castellarin A. A., Nasir M. A., Giust M. J., Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration Ophthalmology 2006 113 3 363 372
117. Bashshur Z. F., Bazarbachi A., Schakal A., Haddad Z. A., El Haibi C. P., Noureddin B. N., Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration American Journal of Ophthalmology 2006 142 1 1 9
118. Spaide R. F., Laud K., Fine H. F., Klancnik J. M. Jr., Meyerle C. B., Yannuzzi L. A., Sorenson J., Slakter J., Fisher Y. L., Cooney M. J., Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration Retina 2006 26 4 383 390 (Pubitemid 44197628)
119. Lazic R., Gabric N., Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration Graefe's Archives for Clinical and Experimental Ophthalmology 2007 245 1 68 73
120. Algvere P. V., Sten B., Seregard S., Kvanta A., A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations Acta Ophthalmologica 2008 86 5 482 489
121. Ehrlich R., Weinberger D., Priel E., Axer-Siegel R., Outcome of bevacizumab (Avastin) injection in patients with age-related macular degeneration and low visual acuity Retina 2008 28 9 1302 1307
122. Costagliola C., Romano M., Corte M. D., Perrotta R., Menzione M., Rinaldi M., Semeraro F., Parmeggiani F., Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration: a 12-month follow-up study Retina 2009 29 9 1227 1234
123. Landa G., Amde W., Doshi V., Ali A., McGevna L., Gentile R. C., Muldoon T. O., Walsh J. B., Rosen R. B., Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration Ophthalmologica 2009 223 6 370 375
124. Stepien K. E., Rosenfeld P. J., Puliafito C. A., Feuer W., Shi W., Al-Attar L., Dubovy S. R., Murray T. G., Davis J. L., Lee W. H., Schwartz S. G., Smiddy W. E., Berrocal A. M., Flynn H. W., Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration Retina 2009 29 8 1067 1073
125. Subramanian M. L., Ness S., Abedi G., Ahmed E., Daly M., Feinberg E., Bhatia S., Patel P., Nguyen M., Houranieh A., Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial American Journal of Ophthalmology 2009 148 6 875 882
126. Fong D. S., Custis P., Howes J., Hsu J. W., Intravitreal bevacizumab and ranibizumab for age-related macular degeneration. A multicenter, retrospective study Ophthalmology 2010 117 2 298 302
127. Wu L., Martnez-Castellanos M. A., Quiroz-Mercado H., Arevalo J. F., Berrocal M. H., Farah M. E., Maia M., Roca J. A., Rodriguez F. J., Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the pan-american collaborative retina study group (PACORES) Graefe's Archive for Clinical and Experimental Ophthalmology 2008 246 1 81 87
128. Wong L. J., Desai R. U., Jain A., Feliciano D., Moshfeghi D. M., Sanislo S. R., Blumenkranz M. S., Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease Retina 2008 28 8 1151 1158
129. Raftery J., Clegg A., Jones J., Seng C. T., Lotery A., Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness British Journal of Ophthalmology 2007 91 9 1244 1246
130. Cruess A. F., Zlateva G., Xu X., Soubrane G., Pauleikhoff D., Lotery A., Mones J., Buggage R., Schaefer C., Knight T., Goss T. F., Economic burden of
131. Smiddy W. E., Economic implications of current age-related macular degeneration treatments Ophthalmology 2009 116 3 481 487
132. Chappelow A. V., Kaiser P. K., Neovascular age-related macular degeneration: potential therapies Drugs 2008 68 8 1029 1036
133. Slakter S., CLEAR-IT 2 Investigators, A phase 2, randomized, controlled dose-and interval-ranging study of intravitreal VEGF trap-eye in patients with neovascular age-related macular degeneration: optical coherence tomography (OCT) and fluorescein angiography (FA) outcomes at 1 Year Investigative Ophthalmology Visual Science 2009 50. abstract no. 1890
134. Safety Efficacy Study Evaluating the Combination of Bevasiranib Lucentis Therapy in Wet AMD (COBALT). [ClinicalTrials.gov identifier: NCT00499590], http://clinicaltrials.gov/ct2/show/ NCT00499590
135. Boyer D.S., Ophthotech Anti-PDGF in AMD Study Group, Combined inhibition of platelet derived (PDGF) and vascular endothelial (VEGF) growth factors for the treatment of neovascular age-related macular degeneration (NV-AMD)results of a phase 1 study Investigative Ophthalmology Visual Science 2009 50. abstract no. 1260
136. Jo N., Mailhos C., Ju M., Cheung E., Bradley J., Nishijima K., Robinson G. S., Adamis A. P., Shima D. T., Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization American Journal of Pathology 2006 168 6 2036 2053
137. Siemann D. W., Chaplin D. J., Walicke P. A., A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P) Expert Opinion on Investigational Drugs 2009 18 2 189 197
138. Nambu H., Nambu R., Melia M., Campochiaro P. A., Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization Investigative Ophthalmology Visual Science 2003 44 8 3650 3655
139. Russell S. R., Hudson H. L., Jerdan J. A., Anecortave acetate for the treatment of exudative age-related macular degenerationa review of clinical outcomes Survey of Ophthalmology 2007 52 supplement 1 S79 S90
140. Yasukawa T., Hoffmann S., Eichler W., Friedrichs U., Wang Y. S., Wiedemann P., Inhibition of experimental choroidal neovascularization in rats by an (v)-integrin antagonist Current Eye Research 2004 28 5 359 366
141. Fu Y., Ponce M. L., Thill M., Yuan P., Nam S. W., Csaky K. G., Angiogenesis inhibition and choroidal neovascularization suppression by sustained delivery of an integrin antagonist, EMD478761 Investigative Ophthalmology Visual Science 2007 48 11 5184 5190
142. Capone A. Jr., Gonzalez V. H., Heier J. S., A phase I open-label study of single and repeated doses of intravitreal JSM6427, a small molecule integrin 5 1 antagonist, in neovascular age-related macular degeneration (AMD) Investigative Ophthalmology Visual Science 2009 50. abstract no. 1259
143. Takahashi T., Nakamura T., Hayashi A., Kamei M., Nakabayashi M., Okada A. A., Tomita N., Kaneda Y., Tano Y., Inhibition of experimental choroidal neovascularization by overexpression of tissue inhibitor of metalloproteinases-3 in retinal pigment epithelium cells American Journal of Ophthalmology 2000 130 6 774 781
144. Cano M. V., Karagiannis E. D., Soliman M., Bakir B., Zhuang W., Popel A. S., Gehlbach P. L., A peptide derived from type 1 thrombospondin repeat-containing protein WISP-1 inhibits corneal and choroidal neovascularization Investigative Ophthalmology Visual Science 2009 50 8 3840 3845
145. Takahashi K., Saishin Y., Saishin Y., Mori K., Ando A., Yamamoto S., Oshima Y., Nambu H., Melia M. B., Bingaman D. P., Campochiaro P. A., Topical nepafenac inhibits ocular neovascularization Investigative Ophthalmology Visual Science 2003 44 1 409 415
146. Dejneka N. S., Kuroki A. M., Fosnot J., Tang W., Tolentino M. J., Bennett J., Systemic rapamycin inhibits retinal and choroidal neovascularization in mice Molecular Vision 2004 10 964 972
147. Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis in Patients With Age-Related Macular Degeneration (EMERALD) [ClinicalTrials.gov identifier: NCT00766337], http://clinicaltrials. gov/ct2/show/NCT00766337
148. Regatieri C.V., Dreyfuss J.L., Melo G.B., Dual role of intravitreous infliximab in experimental choroidal neovascularization. Effect on the expression of sulfated glycosaminoglycans Investigative Ophthalmology Visual Science 2009 50 11 5487 5494
149. Olson J. L., Courtney R. J., Mandava N., Intravitreal infliximab and choroidal neovascularization in an animal model Archives of Ophthalmology 2007 125 9 1221 1224
150. Ueta T., Yanagi Y., Tamaki Y., Yamaguchi T., Cerebrovascular accidents in ranibizumab Ophthalmology 2009 116 2 362
151. Parmeggiani F., Costagliola C., Gemmati D., D'Angelo S., Perri P., Scapoli G. L., Catozzi L., Federici F., Sebastiani A., Incorvaia C., Predictive role of coagulation-balance gene polymorphisms in the efficacy of photodynamic therapy with verteporfin for classic choroidal neovascularization secondary to age-related macular degeneration Pharmacogenetics and Genomics 2007 17 12 1039 1046
152. Parmeggiani F., Costagliola C., Gemmati D., Coagulation-balance genetic predictors for efficacy of photodynamic therapy in occult choroidal neovascularization secondary to age-related macular degeneration Investigative Ophthalmology Visual Science 2008 49 7 3100 3106
153. Parmeggiani F., Gemmati D., Costagliola C., Sebastiani A., Incorvaia C., Predictive role of C677T MTHFR polymorphism in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration Pharmacogenomics 2009 10 1 81 95
154. Parmeggiani F., Gemmati D., Costagliola C., Sebastiani A., Incorvaia C., Predictive role of gene polymorphisms affecting thrombin-generation pathway in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration Recent Patents on DNA and Gene Sequences 2009 3 2 114 122
155. Parmeggiani F., Gemmati D., Costagliola C., Semeraro F., D'Angelo S., Perri P., Sebastiani A., Incorvaia C., Impact of coagulation-balance gene predictors on efficacy of photodynamic therapy for choroidal neovascularization in pathologic myopia Ophthalmology 2010 117 3 517 523
156. Goverdhan S. V., Hannan S., Newsom R. B., Luff A. J., Griffiths H., Lotery A. J., An analysis of the CFH Y402H genotype in AMD patients and controls from the UK, and response to PDT treatment Eye 2008 22 6 849 854
157. Chowers I., Meir T., Lederman M., Goldenberg-Cohen N., Cohen Y., Banin E., Averbukh E., Hemo I., Pollack A., Axer-Siegel R., Weinstein O., Hoh J., Zack D. J., Galbinur T., Sequence variants in HTRA1 and LOC387715/ARMS2 and phenotype and response to photodynamic therapy in neovascular age-related macular degeneration in populations from Israel Molecular Vision 2008 14 2263 2271
158. Brantley M. A. Jr., Edelstein S. L., King J. M., Plotzke M. R., Apte R. S., Kymes S. M., Shiels A., Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy Eye 2009 23 3 626 631
159. Brantley M. A. Jr., Fang A. M., King J. M., Tewari A., Kymes S. M., Shiels A., Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab Ophthalmology 2007 114 12 2168 2173
160. Lee A. Y., Raya A. K., Kymes S. M., Shiels A., Brantley M. A. Jr., Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab British Journal of Ophthalmology 2009 93 5 610 613
161. Feng X., Xiao J., Longville B., Tan A. X. J., Wu X. N., Cooper M. N., McAllister I. L., Isaacs T., Palmer L. J., Constable I. J., Complement factor H Y402H and C-reactive protein polymorphism and photodynamic therapy response in age-related macular degeneration Ophthalmology 2009 116 10 1908 1912